Share
Jane Osbourn
Alchemab Therapeutics, a pharmaceutical company focused on developing naturally occurring therapeutic antibodies, has announced the appointment of Co-Founder Jane Osbourn, OBE, FMEDSCI, PhD, as Chief Executive Officer (CEO) and member of the Board.
Osbourn, previously serving as the company’s Chief Scientific Officer (CSO), succeeds Young Kwon, PhD, in the CEO role.
With over 30 years of experience in the biopharmaceutical industry, Jane has played a pivotal role in advancing Alchemab’s platform and drug discovery efforts. Prior to co-founding Alchemab in 2019, she was Vice President of R&D at MedImmune, AstraZeneca’s biologics division, where she contributed to the development of several successful antibody therapies. Jane’s leadership will guide Alchemab as it continues its mission to discover groundbreaking treatments for patients.
Alchemab’s Chair, Kate Bingham, expressed confidence in Jane’s leadership, emphasizing her extensive industry knowledge and contributions to the company’s growth. Outgoing CEO Young Kwon praised Jane’s expertise and her integral role in building Alchemab’s antibody discovery platform, making her the ideal leader for the company’s next phase.
